GC Molecule Antiviral Composition for SARS-CoV-2 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of specific therapeutics or vaccines for SARS-CoV-2, exacerbating the public health issue caused by the highly contagious coronavirus disease 2019 (COVID-19), and existing antiviral compounds are inadequate in effectively inhibiting viral replication.
Innovation Solution
Administering a therapeutically effective amount of the GC molecule or its pharmaceutically acceptable salt, potentially combined with other therapeutic agents like RNA-dependent RNA polymerase inhibitors or interferon, to treat or prevent SARS-CoV-2 infection, either orally or via intravenous/subcutaneous routes, with the GC molecule reducing virus titers by more than 15-fold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral compounds are used, then treatment is provided, but they are inadequate in effectively inhibiting viral replication
Solution Approach 1:
The patent combines multiple antiviral compounds with different mechanisms of action into a single formulation. This merging approach creates synergistic effects that enhance viral replication inhibition beyond what individual compounds can achieve alone, directly addressing the inadequacy of existing single-agent therapies
Solution Approach 2:
The invention uses composite antiviral formulations containing multiple active ingredients with complementary properties. This composite approach allows the treatment to target different stages of the viral lifecycle simultaneously, improving overall effectiveness and reducing the virus titer more profoundly than monotherapies
2Reliability
If combination therapy with multiple agents is used, then a higher barrier against resistant viral strains is created, but device complexity increases
Solution Approach 1:
Multiple antiviral agents with different mechanisms of action are merged into a single coordinated formulation. This approach creates a higher barrier to resistance by simultaneously targeting multiple viral processes, while the unified formulation simplifies administration compared to separate sequential therapies
Solution Approach 2:
The combination therapy formulation serves multiple functions simultaneously: it inhibits viral entry, blocks replication, and prevents assembly/release of new viral particles. This multi-functionality creates comprehensive protection against resistant strains while maintaining a streamlined treatment approach
Data Source
AI summary
The SARS-CoV-2 is highly contagious and has caused coronavirus disease 2019 (COVID-19) outbreaks worldwide. Some embodiments of the present invention relate to a method of ameliorating or treating a subject suffering from a SARS-CoV-2 infection. The method includes administering to the subject an antiviral composition comprising a therapeutically effective amount of a GC molecule or a pharmaceutically acceptable salt thereof.